A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study-Reference-Cited by-同舟云学术

A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study

Published:2020-07-20 Issue:17 Volume:9 Page:6234-6243
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Cobb Patrick Wayne¹,Moon Yong Wha²,Mezei Klára³,Láng István⁴,Bhat Gajanan⁵,Chawla Shanta⁵,Hasal Steven J.⁵^ORCID,Schwartzberg Lee S.⁶^ORCID

Affiliation:

1. St. Vincent's Frontier Cancer Center Frontier Cancer Center Billings MT USA

2. CHA Bundang Medical Center Seongnam Korea

3. Szabolcs‐Szatmár ‐ Bereg County Hospital Nyíregyháza Hungary

4. National Institute of Oncology Budapest Hungary

5. Spectrum Pharmaceuticals, Inc Irvine CA USA

6. West Cancer Center Germantown TN USA

Funder

Spectrum Pharmaceuticals

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3227

Reference31 articles.

1. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim

2. Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor

3. American Society of Clinical Oncology Statement: Biosimilars in Oncology

4. A new approach to drug therapy: Fc‐fusion technology;Pechtner V;Prim Health Care,2017

5. Abstract 1347: in vivo efficacy of eflapegrastim in rats with chemotherapy‐induced neutropenia;Kim YH;Cancer Res,2017

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial;Supportive Care in Cancer;2023-12-16

2. Efficacy and safety of pegfilgrastim biosimilar MD‐110 in patients with breast cancer receiving chemotherapy: Single‐arm phase III;Cancer Medicine;2023-10

3. Recent advances in protein-based nanoparticles and their applications in the delivery of bioactive compounds;International Journal of Food Properties;2023-09-28

4. PEGylated therapeutics in the clinic;Bioengineering & Translational Medicine;2023-09-22

5. Assessing the Optimal Regimen: A Systematic Review and Network Meta-Analysis of the Efficacy and Safety of Long-Acting Granulocyte Colony-Stimulating Factors in Patients with Breast Cancer;Cancers;2023-07-19